China's YolTech Anchors a $230M US Gene-Editing Launch as CARsgen Wins the World's First Solid-Tumor CAR-T Approval

The China-out engine produced a structurally notable deal this week. YolTech Therapeutics (Shanghai) licensed SERP-01 - an investigational in vivo base-editing therapy that corrects the SERPINA1 E342K mutation behind alpha-1 antitrypsin deficiency (AATD) - to Serapha Bio, a newly formed US company. YolTech took an upfront cash payment plus a minority equity stake in Serapha, with eligibility for more than $2B in regulatory and commercial milestones plus tiered royalties, and retained development and commercialization rights for Greater China. Serapha launched with about $230M in private-placement commitments co-led by RA Capital Management and RTW Investments and is reverse-merging into Nasdaq-listed Boundless Bio, with the combined company expected to trade as AATD. The structure - a China-origin asset built into a purpose-formed US biotech underwritten by Western crossover capital - is the same playbook the proposed BINSA legislation flags, and SERP-01 targets the same SERPINA1 E342K mutation as Beam Therapeutics' BEAM-302.

Discovery-stage dealmaking continued. Novartis partnered with Antares Therapeutics - a 2025 Scorpion Therapeutics spinout - to discover small molecules against historically undruggable oncology targets, paying $105M upfront with up to $1.8B in option, development, regulatory and commercial milestones plus tiered royalties (about $1.9B headline). No major M&A (acquisition) was announced in-window. As always, BD professionals should anchor to near-term cash and de-risking; this week again paired modest upfront with large milestone tails on early-stage assets.

June 24, 2026 - China NMPA Approves CARsgen's Satri-cel, the World's First CAR-T for a Solid Tumor (Claudin18.2-Positive Gastric/GEJ Cancer)

China's NMPA approved satricabtagene autoleucel (satri-cel, CT041), an autologous humanized Claudin18.2-directed CAR T-cell therapy, for adults with Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma who have failed at least two prior lines of therapy - the first CAR-T approved anywhere for a solid tumor. In the pivotal Phase 2 CT041-ST-01 study, satri-cel delivered median progression-free survival of 3.25 months versus 1.77 months for physician's-choice chemotherapy, and median overall survival of 7.92 months versus 5.49 months. Satri-cel also holds US FDA RMAT designation in the same indication.

BD Implication: A first-in-class solid-tumor CAR-T from a Chinese developer, with US RMAT in hand, is a high-visibility China-out asset class and a reminder of the China-versus-West cost-of-goods gap. The modest absolute benefit in end-stage gastric cancer tempers Western commercial read-across, but Claudin18.2 is a validated target (zolbetuximab is approved in the first-line setting), making earlier-line and ex-China development the licensing conversation worth flagging.

June 26, 2026 - FDA Approves Viridian's Lumvoa (veligrotug-vvze) for Thyroid Eye Disease with a Class-First Active-and-Chronic Label

The FDA approved Lumvoa (veligrotug-vvze), an IGF-1R inhibitor, for thyroid eye disease (TED) - Viridian Therapeutics' first approved product. The approval was supported by two Phase 3 trials, THRIVE (active TED) and THRIVE-2 (chronic TED), both of which met their primary and secondary endpoints; reductions in proptosis were observed as early as Week 3. Dosing is five intravenous infusions every three weeks over a 12-week course. Lumvoa is the first in its class to carry labeling that spans both active and chronic TED, differentiating it from the incumbent IGF-1R antibody teprotumumab (Tepezza).

BD Implication: A second IGF-1R entrant with a broader (active plus chronic) label and a shorter five-infusion course shows how label breadth and dosing convenience drive differentiation in a single-mechanism market - a recurring thesis for Western buyers weighing China-origin reformulations and next-in-class biologics.

June 23 to June 26, 2026 - FDA Reopens Paths for Three Previously Rejected Cell and Gene Therapies (Capricor, Replimune, Regenxbio)

In a single week the FDA revisited three decisions made under prior agency leadership. On June 23, the FDA scheduled a July 29, 2026 advisory committee meeting for Capricor's deramiocel in Duchenne muscular dystrophy cardiomyopathy, reversing an earlier position that an advisory committee was not indicated. On June 26, the FDA accepted Replimune's third BLA resubmission for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma as a complete Class 1 response, set an August 2, 2026 goal date, and signaled a late-July advisory committee - the first in RP1's history after two prior rejections. And in late June, Regenxbio said it had aligned with the FDA on a path forward for Navsunli (RGX-121) in Hunter syndrome (MPS II) following a February 7, 2026 Complete Response Letter, with a Type A meeting expected in July and a BLA resubmission planned for Q3 2026 on existing data.

BD Implication: A more liberal use of advisory committees and a willingness to reopen prior rejections lowers, at the margin, the regulatory-risk discount on cell and gene therapy assets, including China-origin programs eyeing US filings. It is a regime-specific recalibration, not a blanket easing, so the de-risking value accrues case by case.

Calendar note: Pfizer's Phase 3 miss for sigvotatug vedotin in previously treated non-squamous NSCLC was reviewed and omitted - the asset is an integrin beta-6 (IB6)-directed ADC (not B7-H4, as some secondary coverage stated) and its topline release is dated June 22, 2026, just outside the June 23-30 window.